Durvalumab and Oleclumab in Resectable PDAC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Durvalumab and Oleclumab in Resectable PDAC — Stella

Recruiting

Back to Pancreatic Ductal Adenocarcinoma trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(1 site)

Canada

Princess Margaret Cancer Centre, Toronto, Ontario

Key details

Phase

Safety & dosing

Sponsor

University Health Network, Toronto

Enrollment target

~22 participants

Started

November 2023

Primary completion

October 2026

Age range

18 Years and older

Last updated January 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov